Related Experiment Video
Updated: Jan 4, 2026
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
29.4K
Novel emerging treatments for NMOSD
Krzysztof Selmaj1,2, Igor Selmaj3
1University of Warmia and Mazury, Warszawska 30, 10-082 Olsztyn, Poland. kselmaj@gmail.com.
Neurologia I Neurochirurgia Polska
|October 31, 2019
Summary
New therapies targeting aquaporin-4 (AQP4) and B cells are highly effective for neuromyelitis optica spectrum disorders (NMOSD). These treatments show promising safety profiles and are expected to gain approval, offering new hope for NMOSD patients.
Area of Science:
- Neuroimmunology
- Central Nervous System (CNS) inflammatory diseases
Background:
- Neuromyelitis optica spectrum disorders (NMOSD) are CNS inflammatory demyelinating diseases.
- Discovery of aquaporin-4 (AQP4) autoantibodies significantly advanced NMOSD diagnosis.
- A subset of NMOSD patients may present with anti-myelin oligodendrocyte glycoprotein (MOG) antibodies.
Purpose of the Study:
- To review recent advancements in NMOSD treatment.
- To evaluate the efficacy and safety of novel therapeutic strategies.
Main Methods:
- Evaluation of monoclonal antibodies (mAbs) targeting complement, IL-6 receptor, and B cells.
- Review of clinical trial data on new NMOSD therapeutics.
Main Results:
- Novel mAbs demonstrate high efficacy in reducing NMOSD activity and preventing disability.
- These new treatments exhibit favorable safety and tolerability profiles.
- Eculizumab is the first approved therapy, with others anticipated.
Conclusions:
- Recent therapeutic developments offer effective and safe options for NMOSD management.
- Targeted therapies represent a significant breakthrough in treating NMOSD.
- Further approvals are expected, improving patient outcomes.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
741
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
741
01:22Alzheimer's Disease: Treatment
722
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
722
01:24Treatment Strategies for Psychological Disorders
531
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
531
01:28Drug Therapy
224
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
224
01:24Parkinson's Disease: Treatment
909
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
909
01:20Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K